Skip to Content
Exit Menu
Dr Victor Hernandez

Dr Victor Hernandez
Lecturer in Biomedical Sciences

Topics

PhD opportunities

https://www.findaphd.com/phds/project/central-nervous-system-gene-therapy-to-treat-obesity-bardet-biedl-syndrome-bbs-analysis-of-the-bbs-brain-development/?p109407

PhD projects for research students

Central Nervous system Gene therapy to treat obesity Bardet-Biedl Syndrome (BBS). Analysis of the BBS brain development

Bardet-Biedl syndrome (BBS) is a debilitating, often life-limiting heritable multisystem disorder caused by dysfunction of non-motile cilia (ciliopathy). There is currently no cure for BBS, a disease characterised by early onset blindness, severe obesity, complex endocrine dysfunction, cognitive impairment and renal failure. Obesity, learning difficulties and behavioural deficits in BBS patients are always being linked to Central Nervous System (CNS) dysfunction. It has been reported CNS abnormalities in brain patients and adult BBS mouse models. Those morphological defects usually consist in enlarged ventricles and reduced mass of the hippocampus and striatum. However, it is unknown the development and/or degeneration of those affected brain areas and it is also not clear how their disruption modulate the phenotype in BBS animal models. Studying the hippocampal-hypothalamic regions development in Bbs1 and Bbs5 mutant mice lines will help to understand how the BBS genes regulate these pathways. Our group is developing gene therapy protocols in order to treat BBS patients. We are using Bbs1M390R/M390R knock-in mice as an animal model to test our viral constructs. We design Adeno-associated virus (AAV) to transduce a BBS1 human copy delivered intracranially. There are different features that can be checked on those animals to analyse the efficacy of the gene therapy; from the recovery of the retinal thickness or the recovery of the animal weight. However, we lack of a robust molecular readout to monitor if the treatment is efficient in the CNS. The aim of this project is to find features that can be quantified to be used in the future to test the efficacy of treatments. We will analyse the differences between mutants and control brains, studying a time series including juvenile and mature brains. We will focus specially in the treatment of hippocampal and hypothalamic areas that have been shown to possibly be affected in BBS patients. Details of the project can be asked in advanced. 

Central Nervous system Gene therapy to treat obesity Bardet-Biedl Syndrome (BBS). Analysis of the BBS brain development

Bardet-Biedl syndrome (BBS) is a debilitating, often life-limiting heritable multisystem disorder caused by dysfunction of non-motile cilia (ciliopathy). There is currently no cure for BBS, a disease characterised by early onset blindness, severe obesity, complex endocrine dysfunction, cognitive impairment and renal failure. Obesity, learning difficulties and behavioural deficits in BBS patients are always being linked to Central Nervous System (CNS) dysfunction.

It has been reported CNS abnormalities in brain patients and adult BBS mouse models. Those morphological defects usually consist in enlarged ventricles and reduced mass of the hippocampus and striatum. However, it is unknown the development and/or degeneration of those affected brain areas and it is also not clear how their disruption modulate the phenotype in BBS animal models. Studying the hippocampal-hypothalamic regions development in Bbs1 and Bbs5 mutant mice lines will help to understand how the BBS genes regulate these pathways.

Our group is developing gene therapy protocols in order to treat BBS patients. We are using Bbs1M390R/M390R knock-in mice as an animal model to test our viral constructs. We design Adeno-associated virus (AAV) to transduce a BBS1 human copy delivered intracranially. There are different features that can be checked on those animals to analyse the efficacy of the gene therapy; from the recovery of the retinal thickness or the recovery of the animal weight. However, we lack of a robust molecular readout to monitor if the treatment is efficient in the CNS.

The aim of this project is to find features that can be quantified to be used in the future to test the efficacy of treatments. We will analyse the differences between mutants and control brains, studying a time series including juvenile and mature brains. We will focus specially in the treatment of hippocampal and hypothalamic areas that have been shown to possibly be affected in BBS patients. Details of the project can be asked in advanced.